Physician profile
Sudha Teerdhala
NPI 1700828548
$4,993.38
in general payments reported to CMS, 2019-2025
51 companies · $1,024 in 2025
The $1,024 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $575 · 2021: $110 · 2022: $351 · 2023: $1,112 · 2024: $1,352 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000 · Long Term Medical Supply Or Device Loan: $299 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,000.34 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $188.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $621.86 | 2023-2025 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Gilead Sciences, INC. | $247.35 | 2019-2025 | Trodelvy |
| Amgen INC. | $213.99 | 2019-2023 | Lumakras |
| Pfizer INC. | $212.93 | 2019-2025 | |
| Stemline Therapeutics INC. | $203.89 | 2023-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $194.05 | 2020-2025 | Opdivo, Eliquis |
| Merck Sharp & Dohme LLC | $189.40 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Tempus Ai, INC | $186.68 | 2024-2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $169.42 | 2020-2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $164.11 | 2021-2025 | Yescarta |
| Incyte Corporation | $156.30 | 2022-2025 | Jakafi, Monjuvi |
| Sirtex Medical INC | $141.73 | 2019-2024 | Sir-Spheres Microspheres |
| Glaxosmithkline, LLC. | $121.04 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $116.64 | 2024-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudha Teerdhala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.